712 North is a pre-clinical stage pharmaceutical company structured around development of modulators of the dynamic mitochondrial network for a range of age-related diseases to include Alzheimer's, cancer, glaucoma, and cardiovascular disease. The firm describes the approach as mitochondria biology with pharmaceutical drug development by targeting the proteases of the mitochondrial inner membrane with small molecules: proteases are highly desired drug targets with implications for many fatal disorders. Arguing that to profile the proteases in a person select ion of the right treatment - rather than reliance on a medical diagnosis - an approach that is engrained in 712 Norths mission statement personalized mitochondrial medicines. To that end,the firm's principals have developed proprietary assays and tools for the molecular diagnosis on one hand and for the development of drugs on the other. The mechanism of action also ties the biology to a rare pediatric indication with unmet medical need. The suggestion is that principal sof the firm may be able to leverage this orphan disease as fast to market strategy.